Monitoring Report: GLP-1 RA Prescribing Trends – March 2025 Data

Samuel Gratzl, PhD*

Brianna M Goodwin Cartwright, MS*

Patricia J Rodriguez, PhD, MPH

Karen Gilbert, PhD

Duy Do, PhD

Nina Masters, MPH, PhD

Nicholas L Stucky, MD, PhD

*Denotes co-first author

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Dr Nicholas Stucky
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: nicholass@truveta.com

Abstract

Background: Limited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity.

For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications.

Objective: To describe recent trends in prescribing and dispensing of GLP-1-based medications in the US.

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were prescribed a GLP-1-based medication between January 01, 2018 and March 31, 2025. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use. Among the subset of patients for whom post-prescription dispensing data is available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription.

Results: 1,970,374 patients were prescribed a GLP-1 RA between January 2018 and March 2025, with 9,376,686 total prescriptions during this period. Among first-time prescriptions for which use could be established, ADMs accounted for 75.8% and AOMs accounted for 24.2%. The most common first-time medication was semaglutide (n = 1,066,552). Among those with available data, 69.1% of first-time ADM prescriptions overall and 71.0% in December 2024 had a fill within 60 days. By comparison, 46.4% of first-time AOM prescriptions overall and 50.5% in December 2024 had a fill within 60 days.

Trends in Prescribing

	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
December 2024	5.26%	2.73%	2.09%	0.07%	0.43%	0.03%
March 2025	5.94%	2.78%	2.75%	0.07%	0.44%	0.03%
Change (percentage)	+12.96%	+1.84%	+31.12%	+3.17%	+2.79%	-4.37%
Difference (percentage points)	+0.68%	+0.05%	+0.65%	+0.00%	+0.01%	-0.00%
ADM						
December 2024	2.75%	1.30%	1.01%	0.01%	0.43%	0.03%
March 2025	2.91%	1.29%	1.18%	0.01%	0.44%	0.03%
Change (percentage)	+5.94%	-0.42%	+16.65%	-45.29%	+2.79%	-4.37%
Difference (percentage points)	+0.16%	-0.01%	+0.17%	-0.00%	+0.01%	-0.00%
AOM						
December 2024	1.41%	0.69%	0.73%	0.01%	n/a	n/a
March 2025	1.65%	0.64%	1.02%	0.01%	n/a	n/a
Change (percentage)	+17.01%	-6.55%	+39.39%	+5.60%		
Difference (percentage points)	+0.24%	-0.04%	+0.29%	+0.00%		
Unknown						

	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
December 2024	1.33%	0.85%	0.44%	0.05%	n/a	n/a
March 2025	1.66%	0.95%	0.67%	0.06%	n/a	n/a
Change (percentage)	+24.85%	+11.54%	+53.24%	+12.15%		
Difference (percentage points)	+0.33%	+0.10%	+0.23%	+0.01%		

- Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in March 2025 increased relative to December 2024 (+12.96%).
- Month-over-month ADM prescribing increased from December 2024 to January 2025, then remained relatively stable until March 2025.
- Among ADMs, semaglutide was the most prescribed medication.
- AOM prescribing increased in March 2025 compared to December 2024 (+17.01%).
- Tirzepatide was the most prescribed AOM, followed by AOM semaglutide.

Trends in First-Time Prescribing

	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
December 2024	1.10%	0.62%	0.41%	0.01%	0.05%	0.01%
March 2025	1.24%	0.60%	0.57%	0.01%	0.05%	0.01%
Change (percentage)	+12.02%	-3.22%	+38.03%	+4.08%	-8.12%	-2.38%
Difference (percentage points)	+0.13%	-0.02%	+0.16%	+0.00%	-0.00%	-0.00%
ADM						
December 2024	0.43%	0.22%	0.14%	0.00%	0.05%	0.01%
March 2025	0.40%	0.19%	0.15%	0.00%	0.05%	0.01%
Change (percentage)	-6.56%	-15.39%	+8.11%	-42.81%	-8.12%	-2.38%
Difference (percentage points)	-0.03%	-0.03%	+0.01%	-0.00%	-0.00%	-0.00%
AOM						
December 2024	0.34%	0.16%	0.18%	0.00%	n/a	n/a
March 2025	0.41%	0.14%	0.26%	0.00%	n/a	n/a
Change (percentage)	+18.63%	-11.75%	+46.37%	+11.67%		
Difference (percentage points)	+0.06%	-0.02%	+0.08%	+0.00%		
Unknown						
December 2024	0.34%	0.24%	0.09%	0.01%	n/a	n/a
March 2025	0.43%	0.27%	0.16%	0.01%	n/a	n/a
Change (percentage)	+29.05%	+14.09%	+68.64%	+14.30%		
Difference (percentage points)	+0.10%	+0.03%	+0.06%	+0.00%		

- First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in March 2025 increased compared to rates in December 2024 (+12.02%).
- First-time prescribing of ADMs decreased slightly in March 2025, relative to December 2024 (-6.56%).
- First-time prescribing of AOMs increased from December 2024 to January 2025, before remaining relatively stable until March 2025 (+18.63%).

Trends in Dispensing

Changes in GLP-1 RA Initiation: Proportion of First-Time GLP-1 RA Prescriptions Dispensed within 60 days between August 2024 and December 2024

	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
September 2024	55.30%	52.31%	57.57%	59.52%	74.46%	60.27%
December 2024	55.65%	53.00%	56.98%	64.27%	74.79%	57.53%
Change (percentage)	+0.63%	+1.31%	-1.03%	+7.98%	+0.44%	-4.56%
Difference (percentage points)	+0.35%	+0.69%	-0.59%	+4.75%	+0.33%	-2.75%
ADM						
September 2024	69.71%	68.28%	70.28%	85.56%	74.46%	60.27%
December 2024	71.04%	68.52%	73.98%	80.00%	74.79%	57.53%
Change (percentage)	+1.92%	+0.35%	+5.27%	-6.49%	+0.44%	-4.56%
Difference (percentage points)	+1.34%	+0.24%	+3.70%	-5.56%	+0.33%	-2.75%
AOM						
September 2024	50.73%	46.93%	55.29%	49.15%	n/a	n/a
December 2024	50.51%	48.31%	52.37%	62.07%	n/a	n/a
Change (percentage)	-0.43%	+2.92%	-5.28%	+26.28%		
Difference (percentage points)	-0.22%	+1.37%	-2.92%	+12.92%		
Unknown						
September 2024	40.67%	41.13%	38.09%	53.01%	n/a	n/a
December 2024	41.02%	41.33%	38.86%	60.27%	n/a	n/a
Change (percentage)	+0.86%	+0.48%	+2.01%	+13.70%		
Difference (percentage points)	+0.35%	+0.20%	+0.77%	+7.26%		

- During the full time period, 70.9% of GLP-1 RA prescriptions had a dispense within 60 days of their prescription (e.g., were initiated within 60 days).
- For patients first prescribed an ADM in December 2024, 71.0% filled a GLP-1 RA within 60 days. Initiation rates for ADM GLP-1 RA are about the same in December 2024, relative to September 2024 (+1.92%).
- For patients first prescribed an AOM in December 2024, 50.5% filled a GLP-1 RA within 60 days. Initiation rates for AOM GLP-1 RA are about the same in December 2024, relative to September 2024 (-0.43%).

About this report

This report provides recent trends in the prescribing and dispensing of glucagon-like peptide-1 receptor agonist (GLP-1 RAs)-based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP) over time, by medication, and by FDA-labeled use. We used near real-time, aggregated electronic health record (EHR) data from a collective of US healthcare systems to describe prescribing and dispensing of GLP-1 RA medications from January 2018 to March 2025.

Introduction

Obesity and type 2 diabetes mellitus (T2D) are interconnected epidemics with a high prevalence and individual and combined negative impacts on health (CDC, 2020, Hales, 2020). Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) -based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP), have been shown to improve glycemic control in patients with T2D and reduce weight in patients with and without T2D (Davies, 2015, Davies, 2021, Garvey, 2023, Jastreboff, 2022, Wilding, 2023, Yeh, 2023). GLP-1 RA have also demonstrated cardiovascular benefit in patients with and without T2D (Lincoff, 2023, Ussher, 2023).

Interest in these medications has recently accelerated, largely for their weight-loss effects; however, limited empiric data exist on prescribing, dispensing, and patient characteristics. Access to and use of GLP-1 RA may be impacted by high cost, limited insurance coverage for patients without T2D and medication shortages.

Methods

Data

We evaluated prescribing and dispensing of GLP-1 RAs between January 2018 and March 2025 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., HbA1c tests and values), and procedures. Updated EHR data are provided daily to Truveta by member health care systems. In addition to EHR data for care delivered within Truveta member health care systems, medication dispensing and social drivers of health (SDOH)

information are made available through linked third-party data. Medication dispense (via e-prescribing data) includes fills for prescriptions written both within and outside Truveta member health care systems, providing greater observability into patients' medication history. Medication dispense histories are updated at the time of the encounter and include fill dates, NDC or RxNorm codes, quantity dispensed, and days of medication supplied.

Population

We identified GLP-1 RA prescriptions (medication requests) and dispenses among adults using RxNorm and NDC codes for dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide. Exenatide and lixisenatide were grouped as 'other' given small relative sizes. Brands were identified when possible using RxNorm and NDC codes. Brands labeled for treatment of T2D were classified as ADMs and brands labeled for treatment of overweight and obesity were classified as AOMs. When brand could not be established, the labeled use was classified as unknown.

Prescribing Analysis

Characteristics of patients ever prescribed a GLP-1 RA were summarized, including demographics, social drivers of health (SDOH), and presence of T2D and/or overweight or obesity. Characteristics are provided by medication and by year of first prescription.

Overall and first-time prescribing rates of GLP-1 RA were summarized over time by medication and labeled use. The prescribing rate was calculated monthly as the number of patients with a GLP-1 RA prescription divided by the number of patients with any prescription in the month. Absolute differences and percentage changes in the rate of GLP-1 RA prescribing over the most recent 3-month period were summarized overall and by medication and labeled use.

Dispensing Analysis

We describe the proportion of GLP-1 RA prescriptions (overall and first-time) with a dispense occurring within 60 days. Dispensing analyses were restricted to prescriptions for which complete 60-day dispensing outcomes could be observed. Dispensing outcomes were considered observable if (1) a dispense was recorded in the 60 days following the prescription, and/or (2) an encounter took place after the 60-day period ended (at which time any dispenses would be observed). To allow sufficient follow-up, we report dispensing with a 90-day delay. Given shortages and expected substitutions at the pharmacy, we considered the dispense of any GLP-1 RA , which could differ from the prescribed GLP-1 RA.

We plot the proportion of prescriptions (overall and first-time) dispensed within 60 days over time, by medication and use. Differences in dispensing were expected between ADMs and AOMs given ADMs are typically covered by insurance, whereas insurance coverage for AOMs is limited. As such, we provide dispensing rates stratified by FDA labeled use. Further, we stratify dispensing by age 65+ vs. 18-64 as a proxy for Medicare coverage. Medicare never provides coverage for AOMs, whereas commercial insurers may.

Results

Overall population

The demographics of patients by first-prescribed medication are as follows:

Table 1: Patient Characteristics by First-Prescribed GLP-1 RA Medication.

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
N	1,066,552 (100.00%)	338,953 (100.00%)	146,844 (100.00%)	308,546 (100.00%)	41,631 (100.00%)	1,902,526 (100.00%)
Age Group						
18-44	281,084 (26.35%)	107,896 (31.83%)	39,569 (26.95%)	44,069 (14.28%)	4,735 (11.37%)	477,353 (25.09%)
45-64	518,760 (48.64%)	169,776 (50.09%)	73,041 (49.74%)	155,518 (50.40%)	19,518 (46.88%)	936,613 (49.23%)
65+	266,708 (25.01%)	61,281 (18.08%)	34,234 (23.31%)	108,959 (35.31%)	17,378 (41.74%)	488,560 (25.68%)
Sex						
Female	696,940 (65.35%)	230,266 (67.93%)	99,419 (67.70%)	166,503 (53.96%)	22,525 (54.11%)	1,215,653 (63.90%)
Male	369,612 (34.65%)	108,687 (32.07%)	47,425 (32.30%)	142,043 (46.04%)	19,106 (45.89%)	686,873 (36.10%)
Race						
White	738,361 (69.23%)	243,874 (71.95%)	102,836 (70.03%)	199,437 (64.64%)	29,562 (71.01%)	1,314,070 (69.07%)
Black or African American	132,365 (12.41%)	37,442 (11.05%)	18,245 (12.42%)	42,923 (13.91%)	4,222 (10.14%)	235,197 (12.36%)
Asian	25,579 (2.40%)	6,831 (2.02%)	2,600 (1.77%)	7,733 (2.51%)	976 (2.34%)	43,719 (2.30%)
Unknown	115,654 (10.84%)	34,483 (10.17%)	15,348 (10.45%)	40,450 (13.11%)	4,785 (11.49%)	210,720 (11.08%)
Native Hawaiian or Other Pacific Islander	3,594 (0.34%)	913 (0.27%)	619 (0.42%)	1,186 (0.38%)	162 (0.39%)	6,474 (0.34%)
American Indian or Alaska Native	7,327 (0.69%)	1,826 (0.54%)	1,500 (1.02%)	2,182 (0.71%)	354 (0.85%)	13,189 (0.69%)
Other Race	43,672 (4.09%)	13,584 (4.01%)	5,696 (3.88%)	14,635 (4.74%)	1,570 (3.77%)	79,157 (4.16%)
Ethnicity						

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
Hispanic or Latino	129,076 (12.10%)	40,495 (11.95%)	16,726 (11.39%)	42,648 (13.82%)	5,068 (12.17%)	234,013 (12.30%)
Not Hispanic or Latino	878,444 (82.36%)	279,338 (82.41%)	121,126 (82.49%)	245,889 (79.69%)	33,612 (80.74%)	1,558,409 (81.91%)
Unknown	59,032 (5.53%)	19,120 (5.64%)	8,992 (6.12%)	20,009 (6.48%)	2,951 (7.09%)	110,104 (5.79%)
Characteristics						
Type II Diabetes	462,615 (43.37%)	110,981 (32.74%)	68,571 (46.70%)	219,095 (71.01%)	28,903 (69.43%)	890,165 (46.79%)
Overweight or Obesity	761,140 (71.36%)	250,485 (73.90%)	92,521 (63.01%)	167,565 (54.31%)	21,181 (50.88%)	1,292,892 (67.96%)
Labeled Use						
ADM	473,222 (44.37%)	169,475 (50.00%)	50,269 (34.23%)	308,546 (100.00%)	41,631 (100.00%)	1,043,143 (54.83%)
AOM	202,439 (18.98%)	100,576 (29.67%)	29,399 (20.02%)	n/a	n/a	332,414 (17.47%)
Unknown	390,891 (36.65%)	68,902 (20.33%)	67,176 (45.75%)	n/a	n/a	526,969 (27.70%)
Year						
2018	3,656 (0.34%)	n/a	25,789 (17.56%)	22,138 (7.17%)	9,279 (22.29%)	60,862 (3.20%)
2019	17,225 (1.62%)	n/a	24,108 (16.42%)	28,790 (9.33%)	7,638 (18.35%)	77,761 (4.09%)
2020	30,182 (2.83%)	n/a	18,258 (12.43%)	31,215 (10.12%)	5,995 (14.40%)	85,650 (4.50%)
2021	68,975 (6.47%)	n/a	21,902 (14.92%)	46,989 (15.23%)	4,823 (11.59%)	142,689 (7.50%)
2022	159,536 (14.96%)	24,604 (7.26%)	24,546 (16.72%)	67,209 (21.78%)	4,878 (11.72%)	280,773 (14.76%)
2023	354,165 (33.21%)	68,797 (20.30%)	22,035 (15.01%)	68,544 (22.22%)	4,646 (11.16%)	518,187 (27.24%)
2024	358,056 (33.57%)	180,721 (53.32%)	8,866 (6.04%)	37,377 (12.11%)	3,683 (8.85%)	588,703 (30.94%)
2025	74,757 (7.01%)	64,831 (19.13%)	1,340 (0.91%)	6,284 (2.04%)	689 (1.66%)	147,901 (7.77%)
Comorbidity						
Asthma	155,496 (14.58%)	49,909 (14.72%)	21,580 (14.70%)	36,060 (11.69%)	4,532 (10.89%)	267,577 (14.06%)
CKD	133,030 (12.47%)	29,741 (8.77%)	19,384 (13.20%)	56,156 (18.20%)	7,494 (18.00%)	245,805 (12.92%)
COPD	53,527 (5.02%)	12,769 (3.77%)	8,504 (5.79%)	21,701 (7.03%)	3,113 (7.48%)	99,614 (5.24%)
Hyperlipidemia	556,557 (52.18%)	162,142 (47.84%)	65,349 (44.50%)	169,406 (54.90%)	22,742 (54.63%)	976,196 (51.31%)
Hypertension	574,002 (53.82%)	163,432 (48.22%)	74,642 (50.83%)	183,341 (59.42%)	24,715 (59.37%)	1,020,132 (53.62%)
Major Depression	134,461 (12.61%)	39,838 (11.75%)	18,934 (12.89%)	29,407 (9.53%)	3,877 (9.31%)	226,517 (11.91%)

Prescribing over time

Overall

We describe the monthly rate of prescriptions by medication and FDA labeled use over time:

First-time

We describe the monthly rate of first-time prescriptions by medication and FDA labeled use over time.

Characteristics of patients by year of first GLP-1 RA use are as follows:

Table 2: Patient Characteristics by Year of First GLP-1 RA Prescription.

	2018	2019	2020	2021	2022	2023	2024
N	60,862 (100.00%)	77,761 (100.00%)	85,650 (100.00%)	142,689 (100.00%)	280,773 (100.00%)	518,187 (100.00%)	588,703 (100.00%)
Age Group							
18-44	9,876 (16.23%)	12,783 (16.44%)	14,678 (17.14%)	27,939 (19.58%)	68,072 (24.24%)	137,614 (26.56%)	163,168 (27.72%)
45-64	33,733 (55.43%)	41,475 (53.34%)	44,824 (52.33%)	72,591 (50.87%)	140,526 (50.05%)	256,933 (49.58%)	278,994 (47.39%)
65+	17,253 (28.35%)	23,503 (30.22%)	26,148 (30.53%)	42,159 (29.55%)	72,175 (25.71%)	123,640 (23.86%)	146,541 (24.89%)
Sex							
Female	33,975 (55.82%)	42,994 (55.29%)	47,141 (55.04%)	83,658 (58.63%)	179,100 (63.79%)	343,843 (66.36%)	389,772 (66.21%)

	2018	2019	2020	2021	2022	2023	2024
Male	26,887 (44.18%)	34,767 (44.71%)	38,509 (44.96%)	59,031 (41.37%)	101,673 (36.21%)	174,344 (33.64%)	198,931 (33.79%)
Race							
White	44,113 (72.48%)	55,692 (71.62%)	60,151 (70.23%)	99,646 (69.83%)	195,562 (69.65%)	355,705 (68.64%)	402,249 (68.33%)
Black or African American	6,992 (11.49%)	8,790 (11.30%)	9,972 (11.64%)	17,660 (12.38%)	35,601 (12.68%)	68,753 (13.27%)	70,311 (11.94%)
Asian	1,206 (1.98%)	1,779 (2.29%)	2,172 (2.54%)	3,986 (2.79%)	6,633 (2.36%)	11,330 (2.19%)	13,248 (2.25%)
Unknown	6,349 (10.43%)	8,102 (10.42%)	9,187 (10.73%)	13,919 (9.75%)	27,213 (9.69%)	54,618 (10.54%)	72,311 (12.28%)
Native Hawaiian or Other Pacific Islander	209 (0.34%)	277 (0.36%)	343 (0.40%)	585 (0.41%)	1,068 (0.38%)	1,644 (0.32%)	1,897 (0.32%)
American Indian or Alaska Native	449 (0.74%)	613 (0.79%)	640 (0.75%)	1,210 (0.85%)	2,191 (0.78%)	3,410 (0.66%)	3,807 (0.65%)
Other Race	1,544 (2.54%)	2,508 (3.23%)	3,185 (3.72%)	5,683 (3.98%)	12,505 (4.45%)	22,727 (4.39%)	24,880 (4.23%)
Ethnicity							
Hispanic or Latino	5,755 (9.46%)	8,117 (10.44%)	9,871 (11.52%)	17,866 (12.52%)	36,848 (13.12%)	64,231 (12.40%)	73,391 (12.47%)
Not Hispanic or Latino	51,271 (84.24%)	64,519 (82.97%)	70,312 (82.09%)	116,473 (81.63%)	228,431 (81.36%)	424,914 (82.00%)	481,591 (81.81%)
Unknown	3,836 (6.30%)	5,125 (6.59%)	5,467 (6.38%)	8,350 (5.85%)	15,494 (5.52%)	29,042 (5.60%)	33,721 (5.73%)
Characteristics							
Type II Diabetes	42,875 (70.45%)	57,807 (74.34%)	61,328 (71.60%)	92,151 (64.58%)	145,341 (51.76%)	224,820 (43.39%)	215,967 (36.69%)
Overweight or Obesity	39,813 (65.42%)	49,728 (63.95%)	52,308 (61.07%)	91,588 (64.19%)	180,888 (64.42%)	352,548 (68.03%)	416,757 (70.79%)
Medication							
Semaglutide	3,656 (6.01%)	17,225 (22.15%)	30,182 (35.24%)	68,975 (48.34%)	159,536 (56.82%)	354,165 (68.35%)	358,056 (60.82%)
Tirzepatide	n/a	n/a	n/a	n/a	24,604 (8.76%)	68,797 (13.28%)	180,721 (30.70%)
Liraglutide	25,789 (42.37%)	24,108 (31.00%)	18,258 (21.32%)	21,902 (15.35%)	24,546 (8.74%)	22,035 (4.25%)	8,866 (1.51%)
Dulaglutide	22,138 (36.37%)	28,790 (37.02%)	31,215 (36.44%)	46,989 (32.93%)	67,209 (23.94%)	68,544 (13.23%)	37,377 (6.35%)
Other	9,279 (15.25%)	7,638 (9.82%)	5,995 (7.00%)	4,823 (3.38%)	4,878 (1.74%)	4,646 (0.90%)	3,683 (0.63%)
Labeled Use							
ADM	37,382 (61.42%)	46,030 (59.19%)	59,307 (69.24%)	104,202 (73.03%)	196,521 (69.99%)	294,615 (56.85%)	254,919 (43.30%)
AOM	1,815 (2.98%)	2,252 (2.90%)	3,363 (3.93%)	8,732 (6.12%)	20,311 (7.23%)	85,559 (16.51%)	162,949 (27.68%)
Unknown	21,665 (35.60%)	29,479 (37.91%)	22,980 (26.83%)	29,755 (20.85%)	63,941 (22.77%)	138,013 (26.63%)	170,835 (29.02%)

	2018	2019	2020	2021	2022	2023	2024
Comorbidity							
Asthma	6,841 (11.24%)	9,668 (12.43%)	10,809 (12.62%)	19,106 (13.39%)	38,061 (13.56%)	73,544 (14.19%)	86,663 (14.72%)
CKD	9,741 (16.01%)	13,966 (17.96%)	16,207 (18.92%)	25,503 (17.87%)	38,775 (13.81%)	60,049 (11.59%)	65,053 (11.05%)
COPD	3,774 (6.20%)	5,203 (6.69%)	5,903 (6.89%)	8,800 (6.17%)	14,410 (5.13%)	25,304 (4.88%)	28,811 (4.89%)
Hyperlipidemia	34,666 (56.96%)	46,801 (60.19%)	49,920 (58.28%)	79,575 (55.77%)	142,760 (50.85%)	254,523 (49.12%)	291,431 (49.50%)
Hypertension	36,738 (60.36%)	49,921 (64.20%)	52,880 (61.74%)	84,563 (59.26%)	151,274 (53.88%)	268,102 (51.74%)	299,689 (50.91%)
Major Depression	6,180 (10.15%)	9,057 (11.65%)	10,288 (12.01%)	18,936 (13.27%)	35,909 (12.79%)	60,540 (11.68%)	67,609 (11.48%)

60-day dispensing over time

We describe the proportion of patients with any GLP-1 RA prescriptions (first-time and repeat) in a given month who filled any GLP-1 RA in the 60 days following their prescription.

60-day initiation over time

We describe the proportion of patients first-prescribed a GLP-1 RA who filled any GLP-1 RA in the subsequent 60 days over time.

Patient characteristics are given in Table 3:

Table 3: Patient Characteristics by Dispense Status. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	1,056,960 (100.00%)	720,498 (100.00%)	1,777,458 (100.00%)
Age Group			
18-44	234,735 (22.21%)	205,457 (28.52%)	440,192 (24.77%)
45-64	534,995 (50.62%)	344,996 (47.88%)	879,991 (49.51%)
65+	287,230 (27.18%)	170,045 (23.60%)	457,275 (25.73%)
Sex			
Female	654,100 (61.89%)	481,033 (66.76%)	1,135,133 (63.86%)
Male	402,860 (38.11%)	239,465 (33.24%)	642,325 (36.14%)
Race			
White	717,888 (67.92%)	510,905 (70.91%)	1,228,793 (69.13%)
Black or African American	131,642 (12.45%)	89,818 (12.47%)	221,460 (12.46%)
Asian	26,589 (2.52%)	14,805 (2.05%)	41,394 (2.33%)
Unknown	123,624 (11.70%)	70,042 (9.72%)	193,666 (10.90%)
Native Hawaiian or Other Pacific Islander	3,888 (0.37%)	2,258 (0.31%)	6,146 (0.35%)
American Indian or Alaska Native	7,541 (0.71%)	4,862 (0.67%)	12,403 (0.70%)
Other Race	45,788 (4.33%)	27,808 (3.86%)	73,596 (4.14%)
Ethnicity			
Hispanic or Latino	133,099 (12.59%)	85,881 (11.92%)	218,980 (12.32%)
Not Hispanic or Latino	861,983 (81.55%)	596,505 (82.79%)	1,458,488 (82.05%)
Unknown	61,878 (5.85%)	38,112 (5.29%)	99,990 (5.63%)
Characteristics			
Type II Diabetes	578,162 (54.70%)	271,919 (37.74%)	850,081 (47.83%)
Overweight or Obesity	697,563 (66.00%)	531,930 (73.83%)	1,229,493 (69.17%)
Medication			
Semaglutide	566,491 (53.60%)	433,291 (60.14%)	999,782 (56.25%)
Tirzepatide	182,961 (17.31%)	118,491 (16.45%)	301,452 (16.96%)
Liraglutide	77,242 (7.31%)	64,064 (8.89%)	141,306 (7.95%)
Dulaglutide	207,820 (19.66%)	87,224 (12.11%)	295,044 (16.60%)
Other	22,446 (2.12%)	17,428 (2.42%)	39,874 (2.24%)
Labeled Use			
ADM	683,316 (64.65%)	305,084 (42.34%)	988,400 (55.61%)
AOM	141,334 (13.37%)	163,541 (22.70%)	304,875 (17.15%)
Unknown	232,310 (21.98%)	251,873 (34.96%)	484,183 (27.24%)
Year			
2018	30,100 (2.85%)	29,705 (4.12%)	59,805 (3.36%)
2019	42,959 (4.06%)	33,147 (4.60%)	76,106 (4.28%)
2020	47,735 (4.52%)	36,188 (5.02%)	83,923 (4.72%)
2021	86,087 (8.14%)	54,012 (7.50%)	140,099 (7.88%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
2022	176,709 (16.72%)	96,507 (13.39%)	273,216 (15.37%)
2023	310,873 (29.41%)	194,488 (26.99%)	505,361 (28.43%)
2024	309,359 (29.27%)	240,472 (33.38%)	549,831 (30.93%)
2025	53,138 (5.03%)	35,979 (4.99%)	89,117 (5.01%)
Comorbidity			
Asthma	144,151 (13.64%)	109,596 (15.21%)	253,747 (14.28%)
CKD	149,361 (14.13%)	87,194 (12.10%)	236,555 (13.31%)
COPD	58,533 (5.54%)	36,435 (5.06%)	94,968 (5.34%)
Hyperlipidemia	557,768 (52.77%)	370,696 (51.45%)	928,464 (52.24%)
Hypertension	578,406 (54.72%)	387,173 (53.74%)	965,579 (54.32%)
Major Depression	118,520 (11.21%)	99,655 (13.83%)	218,175 (12.27%)

By Age

As a proxy for Medicare insurance, we segment initiation rate by populations 65+ versus 18-64.

Patient characteristics for patients aged 65+ are given in Table 4:

Table 4: Patient Characteristics by Dispense Status, Age 65+. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	287,230 (100.00%)	170,045 (100.00%)	457,275 (100.00%)
Age Group			
65+	287,230 (100.00%)	170,045 (100.00%)	457,275 (100.00%)
Sex			

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
Female	159,214 (55.43%)	96,200 (56.57%)	255,414 (55.86%)
Male	128,016 (44.57%)	73,845 (43.43%)	201,861 (44.14%)
Race			
White	212,775 (74.08%)	131,793 (77.50%)	344,568 (75.35%)
Black or African American	25,401 (8.84%)	14,441 (8.49%)	39,842 (8.71%)
Asian	6,231 (2.17%)	2,814 (1.65%)	9,045 (1.98%)
Unknown	31,433 (10.94%)	15,841 (9.32%)	47,274 (10.34%)
Native Hawaiian or Other Pacific Islander	588 (0.20%)	274 (0.16%)	862 (0.19%)
American Indian or Alaska Native	1,566 (0.55%)	813 (0.48%)	2,379 (0.52%)
Other Race	9,236 (3.22%)	4,069 (2.39%)	13,305 (2.91%)
Ethnicity			
Hispanic or Latino	23,880 (8.31%)	11,407 (6.71%)	35,287 (7.72%)
Not Hispanic or Latino	245,374 (85.43%)	148,587 (87.38%)	393,961 (86.15%)
Unknown	17,976 (6.26%)	10,051 (5.91%)	28,027 (6.13%)
Characteristics			
Type II Diabetes	195,741 (68.15%)	97,283 (57.21%)	293,024 (64.08%)
Overweight or Obesity	180,727 (62.92%)	112,248 (66.01%)	292,975 (64.07%)
Medication			
Semaglutide	154,385 (53.75%)	96,130 (56.53%)	250,515 (54.78%)
Tirzepatide	35,476 (12.35%)	19,410 (11.41%)	54,886 (12.00%)
Liraglutide	17,794 (6.20%)	14,479 (8.51%)	32,273 (7.06%)
Dulaglutide	70,342 (24.49%)	32,828 (19.31%)	103,170 (22.56%)
Other	9,233 (3.21%)	7,198 (4.23%)	16,431 (3.59%)
Labeled Use			
ADM	213,133 (74.20%)	94,149 (55.37%)	307,282 (67.20%)
AOM	10,910 (3.80%)	21,405 (12.59%)	32,315 (7.07%)
Unknown	63,187 (22.00%)	54,491 (32.05%)	117,678 (25.73%)
Year			
2018	8,314 (2.89%)	8,565 (5.04%)	16,879 (3.69%)
2019	12,549 (4.37%)	10,320 (6.07%)	22,869 (5.00%)
2020	14,344 (4.99%)	11,107 (6.53%)	25,451 (5.57%)
2021	25,103 (8.74%)	16,069 (9.45%)	41,172 (9.00%)
2022	45,407 (15.81%)	23,961 (14.09%)	69,368 (15.17%)
2023	82,880 (28.85%)	37,122 (21.83%)	120,002 (26.24%)
2024	83,796 (29.17%)	53,492 (31.46%)	137,288 (30.02%)
2025	14,837 (5.17%)	9,409 (5.53%)	24,246 (5.30%)
Comorbidity			
Asthma	34,640 (12.06%)	21,769 (12.80%)	56,409 (12.34%)
CKD	86,122 (29.98%)	49,601 (29.17%)	135,723 (29.68%)
COPD	29,358 (10.22%)	18,480 (10.87%)	47,838 (10.46%)
Hyperlipidemia	192,574 (67.05%)	120,527 (70.88%)	313,101 (68.47%)
Hypertension	201,735 (70.23%)	126,311 (74.28%)	328,046 (71.74%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
Major Depression	31,478 (10.96%)	20,881 (12.28%)	52,359 (11.45%)

Patient characteristics for patients aged 18-65 are given in Table 5:

Table 5: Patient Characteristics by Dispense Status, Age 18-64. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	769,730 (100.00%)	550,453 (100.00%)	1,320,183 (100.00%)
Age Group			
18-44	234,735 (30.50%)	205,457 (37.33%)	440,192 (33.34%)
45-64	534,995 (69.50%)	344,996 (62.67%)	879,991 (66.66%)
Sex			
Female	494,886 (64.29%)	384,833 (69.91%)	879,719 (66.64%)
Male	274,844 (35.71%)	165,620 (30.09%)	440,464 (33.36%)
Race			
White	505,113 (65.62%)	379,112 (68.87%)	884,225 (66.98%)
Black or African American	106,241 (13.80%)	75,377 (13.69%)	181,618 (13.76%)
Asian	20,358 (2.64%)	11,991 (2.18%)	32,349 (2.45%)
Unknown	92,191 (11.98%)	54,201 (9.85%)	146,392 (11.09%)
Native Hawaiian or Other Pacific Islander	3,300 (0.43%)	1,984 (0.36%)	5,284 (0.40%)
American Indian or Alaska Native	5,975 (0.78%)	4,049 (0.74%)	10,024 (0.76%)
Other Race	36,552 (4.75%)	23,739 (4.31%)	60,291 (4.57%)
Ethnicity			
Hispanic or Latino	109,219 (14.19%)	74,474 (13.53%)	183,693 (13.91%)
Not Hispanic or Latino	616,609 (80.11%)	447,918 (81.37%)	1,064,527 (80.63%)
Unknown	43,902 (5.70%)	28,061 (5.10%)	71,963 (5.45%)
Characteristics			
Type II Diabetes	382,421 (49.68%)	174,636 (31.73%)	557,057 (42.20%)
Overweight or Obesity	516,836 (67.15%)	419,682 (76.24%)	936,518 (70.94%)
Medication			
Semaglutide	412,106 (53.54%)	337,161 (61.25%)	749,267 (56.75%)
Tirzepatide	147,485 (19.16%)	99,081 (18.00%)	246,566 (18.68%)
Liraglutide	59,448 (7.72%)	49,585 (9.01%)	109,033 (8.26%)
Dulaglutide	137,478 (17.86%)	54,396 (9.88%)	191,874 (14.53%)
Other	13,213 (1.72%)	10,230 (1.86%)	23,443 (1.78%)
Labeled Use			
ADM	470,183 (61.08%)	210,935 (38.32%)	681,118 (51.59%)
AOM	130,424 (16.94%)	142,136 (25.82%)	272,560 (20.65%)
Unknown	169,123 (21.97%)	197,382 (35.86%)	366,505 (27.76%)
Year			

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
2018	21,786 (2.83%)	21,140 (3.84%)	42,926 (3.25%)
2019	30,410 (3.95%)	22,827 (4.15%)	53,237 (4.03%)
2020	33,391 (4.34%)	25,081 (4.56%)	58,472 (4.43%)
2021	60,984 (7.92%)	37,943 (6.89%)	98,927 (7.49%)
2022	131,302 (17.06%)	72,546 (13.18%)	203,848 (15.44%)
2023	227,993 (29.62%)	157,366 (28.59%)	385,359 (29.19%)
2024	225,563 (29.30%)	186,980 (33.97%)	412,543 (31.25%)
2025	38,301 (4.98%)	26,570 (4.83%)	64,871 (4.91%)
Comorbidity			
Asthma	109,511 (14.23%)	87,827 (15.96%)	197,338 (14.95%)
CKD	63,239 (8.22%)	37,593 (6.83%)	100,832 (7.64%)
COPD	29,175 (3.79%)	17,955 (3.26%)	47,130 (3.57%)
Hyperlipidemia	365,194 (47.44%)	250,169 (45.45%)	615,363 (46.61%)
Hypertension	376,671 (48.94%)	260,862 (47.39%)	637,533 (48.29%)
Major Depression	87,042 (11.31%)	78,774 (14.31%)	165,816 (12.56%)

Discussion and Conclusion

This analysis summarized GLP-1 RA prescribing trends and patient characteristics from January 2018 to March 2025. During this period 1,970,374 patients were prescribed a total of 9,376,686 total prescriptions. ADMs accounted for 79.6% of prescriptions, and AOMs accounted for 20.4%, among prescriptions where use was known. A larger proportion of ADMs, compared to AOMs, were dispensed within 60 days: 69.1% of first-time ADM prescriptions and 46.4% of first-time AOM prescriptions had a fill within 60 days.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed April 11, 2025. Data presented in this analysis represent raw counts and/or rates, and post-stratification methods have not been conducted. In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Given relatively large numbers of patients prescribed and dispensed GLP-1 RA, we do not expect substantial suppression in the most recent periods. The unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024). Finally, this report is a description of prescribing trends and patient characteristics only. Results should not be interpreted as causal.

References

Truveta. (2024). Truveta's Approach to Patient Privacy.
https://resources.truveta.com/patient-privacy

Centers for disease control and prevention. "National diabetes statistics report". 2020.
https://www.cdc.gov/diabetes/data/statistics-report/index.html.

Davies, Melanie J., et al. "Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial." JAMA 314.7 (2015): 687-699.

Davies, Melanie, et al. "Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial." The Lancet 397.10278 (2021): 971-984.

Hales, Craig M., et al. "Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360." National Center for Health Statistics 360 (2020): 1-7.

Han, Sabrina H., et al. "Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a google trends analysis." Aesthetic Surgery Journal 44.1 (2024): 60-67.

Garvey, W. Timothy, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial." The Lancet (2023).

Jastreboff, Ania M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387.3 (2022): 205-216.

Lincoff, A. Michael, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." New England Journal of Medicine 389.24 (2023): 2221-2232.

Ussher, John R., and Daniel J. Drucker. "Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action." Nature Reviews Cardiology 20.7 (2023): 463-474.

Wilding, John PH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine 384.11 (2021): 989-1002.

Whitley, Heather P., Jennifer M. Trujillo, and Joshua J. Neumiller. "Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages." Clinical Diabetes (2023): cd230023.

Yeh, Tzu-Lin, et al. "Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis." PLOS One 18.1 (2023): e0278685.

Acknowledgements

The authors thank Dr. Ty Gluckman for his contributions and feedback on describing GLP-1 RA prescribing trends.